Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

The Council for Responsible Nutrition announces Dec. 11 Robert Borris, PhD, will become the association's vice president-botanical science and regulatory affairs, effective Jan. 2, 2007. CRN says Borris will be responsible for "increasing the awareness of the evolving body of botanical research that supports an appropriate role for plant-based dietary supplements." Borris previously worked for Merck Research Laboratories for more than two decades, according to the release. He headed the phytochemistry program and its two major biodiversity collaborations with INBio and the New York Botanical Garden, according to CRN. The trade group's President & CEO Steve Mister says: "We are excited to welcome Dr. Borris to CRN's team. His specific expertise makes our well-respected scientific team even stronger and rounds out our coverage of all supplement categories." CRN most recently appointed Andrew Shao, PhD, VP-scientific and regulatory affairs in April 2005 (1"The Tan Sheet" April 4, 2005, In Brief)...

You may also be interested in...

CRN appointment

Andrew Shao, PhD, has been appointed VP-scientific & regulatory affairs for the Council for Responsible Nutrition, the association announces April 1. Shao previously served as a senior scientist for GNC, where he reviewed new products and ingredients to determine their scientific viability and applications. John Hathcock, PhD, will continue to serve as VP-scientific & international affairs. The appointment closely follows that of incoming CRN President Steve Mister, who will assume his role later this month (1"The Tan Sheet" March 14, 2005, p. 8)...

Global Catastrophe Or Passing Nuisance? Pharma’s Coronavirus Views

While the global health threat from the now officially named SARS-CoV-2 coronavirus has grown since the start of the quarterly earnings season in early February, even many of the companies reporting more recently do not appear overly concerned about potential business impact at this stage.

Sanofi Tries To Stop Lantus Biosimilar By Getting Supreme Court To Review PTAB, Again

Sanofi seeks to delay decision clearing path for Mylan's Lantus biosimilar; says it should be able to get rehearing based on Federal Circuit's ruling that PTAB judges were not constitutionally appointed.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts